Humalog®
Insulin Lispro is a rapid-acting insulin analog used for mealtime glycemic control. Modified structure reduces hexamer formation, accelerating absorption.
| Dosage Form | SC Injectable (Prefilled Pen / Vial) |
| Strength | 100 units/mL, 200 units/mL |
| Storage | Store at 2–8°C. After first use, store at room temperature for up to 28 days. |
| Category | Diabetes & GLP-1 |
| Availability | Available for Transfer |
Type 1 and type 2 diabetes mellitus (prandial insulin).
Rapid-acting insulin analog with reversed proline-lysine sequence at positions B28-B29, reducing self-association and enabling faster subcutaneous absorption than regular insulin.
Each Burrard Pharmaceuticals technology transfer package for Insulin Lispro includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.